Skip to content

Does Ozempic make you tired? Fatigue in the GLP-1 labels

By the glp1doses editorial team
Every number is checked against FDA labels and official price pages. How we check

The short answer

Does Ozempic make you tired? Its label names fatigue as a reaction reported at a frequency above 0.4%, outside its main table and with no rate by dose. Five GLP-1 labels list fatigue in their tables: Wegovy (11% of adults on 2.4 mg against 5% on placebo), Zepbound (5% to 7% against 3%), Foundayo, Saxenda and Trulicity. Mounjaro's mentions it outside its main table, and the Rybelsus table doesn't list it.

Key takeaways

  • Five GLP-1 labels list fatigue in their tables. Ozempic's and Mounjaro's mention it elsewhere, and the Rybelsus table doesn't list it.
  • Contact your prescriber sooner if tiredness is severe, sudden, or comes with vomiting, diarrhea, dizziness or fainting.
  • Mention mild, steady fatigue at your next contact.
  • Only the Saxenda label says when fatigue tends to happen: mainly within the first 12 weeks of treatment.
  • Don't change your dose yourself because of tiredness.

How often it was reported in the label's trials

Zepbound: Table 1: Adverse Reactions (≥2% and Greater than Placebo) in ZEPBOUND-Treated Adults with Obesity or Overweight in Weight Reduction and Long-term Maintenance Trials (Study 1 and Study 2) · Pool of two randomized, double-blind, placebo-controlled weight reduction trials (Study 1 and Study 2) that included 2,519 adults with obesity or overweight, with or without type 2 diabetes, treated with Zepbound for up to 72 weeks plus a 4-week off-drug follow-up period.
ReactionPlacebon=9585 mgn=63010 mgn=94815 mgn=941
Fatigue3%5%6%7%

FDA label: Zepbound, Revised: 8/2026 (DailyMed version 40)

Wegovy: Table 3. Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction · Adults with obesity or overweight in 3 randomized, double-blind, placebo-controlled trials, treated with Wegovy 2.4 mg injection for up to 68 weeks plus a 7-week off-drug follow-up. The label shows '<1' for placebo eructation. The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 3: Wegovy N=403, placebo N=402). Abdominal pain, fatigue, gastritis and dysesthesia are grouped terms.
ReactionPlacebon=1261Wegovy injection 2.4 mg once weeklyn=2116
Fatigue5%11%
Wegovy: Table 4. Adverse Reactions (2% and Greater Than WEGOVY 2.4 mg and Placebo) in WEGOVY 7.2 mg Injection-treated Adults with Obesity for Weight Reduction · Adults with obesity (BMI of 30 or more) in two 72-week, double-blind, randomized, placebo-controlled, 3-armed trials (Study 8 and Study 9, the second in patients with type 2 diabetes). Dysesthesia, abdominal pain, fatigue and dizziness are grouped terms.
ReactionPlacebon=303Wegovy injection 2.4 mg once weeklyn=304Wegovy injection 7.2 mg once weeklyn=1311
Fatigue5%9%11%

FDA label: Wegovy, Revised: 6/2026 (DailyMed version 19)

Foundayo: Table 1: Adverse Reactions Reported in ≥5% of FOUNDAYO-treated Adult Patients with Obesity or Overweight (With or Without Type 2 Diabetes) in Pool of Placebo-Controlled Trials (Trials 1 and 2) · Pool of two randomized, double-blind, placebo-controlled weight management trials (Trials 1 and 2) that included 3155 adults with obesity or overweight, with or without type 2 diabetes, treated with Foundayo once daily for up to 72 weeks plus a 2-week off-drug follow-up period.
ReactionPlacebon=15765.5 mgn=10519 mgn=105517.2 mgn=1049
Fatigue4%6%7%9%

FDA label: Foundayo, Revised: 7/2026 (DailyMed version 10)

Saxenda: Table 2. Adverse Reactions Occurring in ≥2% of SAXENDA-treated Adult Patients and More Frequently than Placebo · Adults with overweight or obesity in 5 double-blind, placebo-controlled trials, treated for up to 56 weeks (3 trials), 52 weeks (1 trial) and 32 weeks (1 trial). The hypoglycemia row is for patients with type 2 diabetes not on insulin (Study 2: Saxenda N=423, placebo N=212), defined as blood glucose below 54 mg/dL with or without symptoms.
ReactionPlacebon=1941Saxendan=3384
Fatigue4.6%7.5%
Saxenda: Table 3. Adverse Reactions Occurring in ≥3% of SAXENDA-treated Pediatric Patients and More Frequently than Placebo in a 56 Week Clinical Trial · Pediatric patients aged 12 years and older with obesity, without type 2 diabetes, in a 56-week placebo-controlled trial. The hypoglycemia row is defined as blood glucose below 70 mg/dL with symptoms.
ReactionPlacebon=126Saxendan=125
Fatigue3.2%4.8%

FDA label: Saxenda, Revised: 6/2026 (DailyMed version 22)

Trulicity: Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in ≥5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus · Pool of placebo-controlled trials that included 1,670 adults with type 2 diabetes exposed to Trulicity 0.75 mg or 1.5 mg, with a mean duration of exposure of 23.8 weeks. Hypoglycemia is excluded.
ReactionPlacebon=5680.75 mgn=8361.5 mgn=834
Fatigue2.6%4.2%5.6%

FDA label: Trulicity, Revised: 3/2026 (DailyMed version 62)

Each medicine's figures come from its own trials, which differ in dose, length and who took part. They are not a head-to-head comparison.

Feeling tired on a GLP-1? Mention it at your next contact with your prescriber if it’s mild and steady. Contact them sooner if it’s severe, if it came on suddenly, if it follows a dose increase and doesn’t ease, or if it comes with vomiting, diarrhea, dizziness or fainting.

Fatigue is one of the few common reactions in the GLP-1 labels that isn’t a stomach or bowel symptom. The labels treat it unevenly: five give it a table row, two mention it elsewhere and one doesn’t list it.

The five labels with fatigue in their tables

Each figure is the share of trial patients who reported fatigue, next to the placebo group from the same trials. A placebo group gets an inactive treatment instead of the medicine.

  • Wegovy 2.4 mg injection (adults, three weight reduction trials): 11%, with 5% on placebo. The label counts fatigue as a grouped term that takes in related reports. In the 7.2 mg trials in adults with obesity: 11% on 7.2 mg, 9% on 2.4 mg and 5% on placebo.
  • Foundayo (adults with obesity or overweight, two pooled trials): 6% at 5.5 mg, 7% at 9 mg and 9% at 17.2 mg, with 4% on placebo.
  • Saxenda (adults, five trials): 7.5%, with 4.6% on placebo. The same table has a separate row for asthenia, meaning weakness: 2.1%, with 0.8% on placebo.
  • Zepbound (adults with obesity or overweight, two pooled trials): 5% at 5 mg, 6% at 10 mg and 7% at 15 mg, with 3% on placebo.
  • Trulicity (adults with type 2 diabetes, pooled trials): 4.2% at 0.75 mg and 5.6% at 1.5 mg, with 2.6% on placebo.

In adolescents aged 12 and older with obesity, the Saxenda label reports fatigue in 4.8% on Saxenda and 3.2% on placebo. Fatigue isn’t listed in the Wegovy label’s adolescent table.

In every one of these rows the placebo group reported fatigue too, at between 2.6% and 5%. The gap between the treated and placebo figures runs from under two to six percentage points. The trials are separate and count the term differently, so each gap describes a medicine against its own placebo group, not against the others.

The three labels without a table row

Ozempic. The injection label’s table stops at reactions reported by at least 5% of patients, and fatigue isn’t listed in it. The label’s text says: “Other adverse reactions with a frequency of >0.4% were associated with OZEMPIC include fatigue, dysgeusia and dizziness.” Dysgeusia means taste changes. No rate by dose is given.

Mounjaro. Fatigue isn’t listed in the label’s main table from its placebo-controlled trials. It appears in the description of the cardiovascular outcomes trial in 6,647 adults with type 2 diabetes and established cardiovascular disease, where the label reports fatigue in 10% of patients on Mounjaro.

Rybelsus. Fatigue isn’t listed in the table of the label, which also covers Ozempic tablets.

When does fatigue occur?

One label answers. Saxenda’s says: “Events of asthenia, fatigue, malaise, dysgeusia and dizziness were mainly reported within the first 12 weeks of treatment with SAXENDA and were often co-reported with gastrointestinal events such as nausea, vomiting, and diarrhea.”

Two things follow for Saxenda specifically. The reports clustered early, and tiredness often arrived together with stomach reactions. The label doesn’t say one caused the other.

No warning in our records names fatigue as a symptom. Two warnings are worth knowing about because of what often travels with it:

  • Dehydration. Each label warns of acute kidney injury due to volume depletion (losing too much fluid), with most reported cases in patients whose nausea, vomiting or diarrhea led to dehydration. If tiredness comes with vomiting or diarrhea, report both.
  • Hypoglycemia. Each label warns that low blood sugar is more likely when the medicine is used with insulin or a sulfonylurea, a type of diabetes pill. The Wegovy, Zepbound and Foundayo labels state plainly that the medicine lowers blood glucose and can cause hypoglycemia. Ask your prescriber or pharmacist what to watch for if you take those medicines.

The Zepbound, Foundayo, Wegovy and Saxenda labels also report low blood pressure in their trials. In Zepbound’s pooled trials, hypotension (low blood pressure) occurred in 1.6% of treated patients and 0.1% on placebo.

When to contact your prescriber

Mention fatigue at your next contact if it’s mild and steady. Contact your prescriber sooner if it’s severe, if it appeared suddenly, if it follows a dose increase and doesn’t ease, or if it comes with vomiting, diarrhea, dizziness or fainting. They can check for causes that have nothing to do with the medicine and decide whether anything about your dose should change. Don’t change it yourself.

Related pages: headache, nausea and the side effects overview.

Frequently asked questions

Does Ozempic make you tired?

The Ozempic injection label doesn't put fatigue in its main table, which only lists reactions reported by at least 5% of patients. It names fatigue separately, saying fatigue, dysgeusia (taste changes) and dizziness were other reactions linked to Ozempic at a frequency above 0.4%. It gives no figure by dose and no placebo comparison for fatigue.

Does Zepbound cause fatigue?

Yes, fatigue is in the Zepbound label's table. In two pooled weight reduction trials in adults with obesity or overweight, 5% of patients on 5 mg, 6% on 10 mg and 7% on 15 mg reported it, compared with 3% on placebo. The label doesn't say when fatigue occurred or how long it lasted.

How long does GLP-1 fatigue last?

Only the Saxenda label addresses timing. It says asthenia (weakness), fatigue, malaise (feeling generally unwell), taste changes and dizziness were mainly reported within the first 12 weeks of treatment. It adds that they were often reported along with stomach and bowel events such as nausea, vomiting and diarrhea. No label says how long your own tiredness will last.

Is tiredness on a GLP-1 a sign of something serious?

The labels warn about dehydration from vomiting or diarrhea, and about low blood sugar when these medicines are used with insulin or a sulfonylurea. Tiredness that's severe, sudden or comes with other symptoms is a reason to contact your prescriber, who can check for a cause. That includes extreme fatigue you can't explain.

Does Wegovy make you tired?

Yes, fatigue is in the Wegovy label's table. In three weight reduction trials of the 2.4 mg injection in adults, 11% of patients reported it, compared with 5% on placebo. The label counts fatigue as a grouped term that takes in related reports. In the 7.2 mg trials, it was reported by 11% on 7.2 mg, 9% on 2.4 mg and 5% on placebo.

Sources (8)

  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.